AU2016258326A1 - Nucleic acid-cationic polymer compositions and methods of making and using the same - Google Patents

Nucleic acid-cationic polymer compositions and methods of making and using the same Download PDF

Info

Publication number
AU2016258326A1
AU2016258326A1 AU2016258326A AU2016258326A AU2016258326A1 AU 2016258326 A1 AU2016258326 A1 AU 2016258326A1 AU 2016258326 A AU2016258326 A AU 2016258326A AU 2016258326 A AU2016258326 A AU 2016258326A AU 2016258326 A1 AU2016258326 A1 AU 2016258326A1
Authority
AU
Australia
Prior art keywords
carbohydrate
nucleic acid
poly
cationic polymer
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016258326A
Other languages
English (en)
Inventor
Jennifer GALLULA
Abraham Hochberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2016258326A1 publication Critical patent/AU2016258326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016258326A 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same Abandoned AU2016258326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL23864315 2015-05-05
IL238643 2015-05-05
PCT/IL2016/050477 WO2016178233A1 (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2016258326A1 true AU2016258326A1 (en) 2017-11-23

Family

ID=56134418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016258326A Abandoned AU2016258326A1 (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Country Status (14)

Country Link
US (2) US20180154023A1 (enExample)
EP (1) EP3291799A1 (enExample)
JP (2) JP2018515479A (enExample)
KR (1) KR20180015145A (enExample)
CN (1) CN107735079A (enExample)
AU (1) AU2016258326A1 (enExample)
BR (1) BR112017023788A2 (enExample)
CA (1) CA2984879A1 (enExample)
IL (1) IL255254A0 (enExample)
MX (1) MX2017014060A (enExample)
PH (1) PH12017502216A1 (enExample)
RU (1) RU2017140065A (enExample)
SG (2) SG11201708760PA (enExample)
WO (1) WO2016178233A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法
DE102017003004A1 (de) 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Kationische Polymere mit D-Fructose-Substituenten
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
EP3924463A1 (en) 2019-02-11 2021-12-22 Excellgene SA Novel eukaryotic cell transfection systems and related methods
CN111363761A (zh) * 2020-03-17 2020-07-03 苏州吉恒基因科技有限公司 利用阳离子多聚体dna复合物促进aav介导的基因表达方法
CA3181339A1 (en) * 2020-04-27 2021-11-04 Juno Therapeutics, Inc. Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
WO2022249180A1 (en) 2021-05-25 2022-12-01 Ramot At Tel-Aviv University Ltd. Compositions comprising extracellular vesicles and an active agent and uses thereof
CN113501889A (zh) * 2021-07-06 2021-10-15 郑州大学 一种三七多糖阳离子衍生物的制备方法及其应用
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
CN114762731B (zh) * 2022-05-16 2024-08-23 常州大学 一种延长基因药物在温和条件下储存时间的方法
CN116036043A (zh) * 2023-01-10 2023-05-02 深圳市乐土生物医药有限公司 一种核酸药物制剂、冻干粉及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
JP2009508516A (ja) 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
CA2675967A1 (en) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
CN101820864A (zh) * 2007-08-06 2010-09-01 艾根股份有限公司 核酸-脂聚合物组合物
BRPI0818937B8 (pt) 2007-10-25 2021-05-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd constructos contendo múltiplos cassetes de expressão para terapia de câncer
WO2010028093A2 (en) * 2008-09-03 2010-03-11 Senesco Technologies, Inc. Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
DE102009006606A1 (de) * 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法

Also Published As

Publication number Publication date
IL255254A0 (en) 2017-12-31
EP3291799A1 (en) 2018-03-14
US20200138977A1 (en) 2020-05-07
US20180154023A1 (en) 2018-06-07
RU2017140065A (ru) 2019-06-05
BR112017023788A2 (pt) 2018-10-16
KR20180015145A (ko) 2018-02-12
CN107735079A (zh) 2018-02-23
MX2017014060A (es) 2018-07-06
CA2984879A1 (en) 2016-11-10
JP2021130671A (ja) 2021-09-09
WO2016178233A1 (en) 2016-11-10
RU2017140065A3 (enExample) 2019-09-27
SG11201708760PA (en) 2017-11-29
PH12017502216A1 (en) 2018-06-11
JP2018515479A (ja) 2018-06-14
SG10201909209RA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US20200138977A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
Lai et al. Nucleic acid delivery with chitosan and its derivatives
CA2695901C (en) Nucleic acid-lipopolymer compositions
US9827331B2 (en) Nucleic acid-lipopolymer compositions
Kang et al. Polymeric nucleic acid carriers: current issues and novel design approaches
Ito et al. DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice
CA2915131A1 (en) Freeze-dried polyelectrolyte complexes that maintain size and biological activity
Yan et al. Nanomedicine for gene delivery for the treatment of cardiovascular diseases
Zhang et al. Combination of sequence‐defined oligoaminoamides with transferrin‐polycation conjugates for receptor‐targeted gene delivery
Wang et al. NIR-light and GSH activated cytosolic p65-shRNA delivery for precise treatment of metastatic cancer
Mohammad Key considerations in formulation development for gene therapy products
Zhou et al. Polyplex nanovesicles of single strand oligonucleotides for efficient cytosolic delivery of biomacromolecules
JP2020172534A (ja) 合成脳浸透遺伝子ベクターの操作
Duskunovic et al. Effective mRNA delivery by condensation with cationic nanogels incorporated into liposomes
Zhang et al. Chondroitin sulfate modified calcium phosphate nanoparticles for efficient transfection via caveolin-mediated endocytosis
Liu et al. PH-sensitive self-assembled carboxymethyl chitosan-modified DNA/polyethylenimine complexes for efficient gene delivery
HK1247839A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
Singh et al. The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions
Jiang et al. Poly (amido amine)-based nanogels for delivery of mRNA
EP4124345A1 (en) Nanoparticles for muscle delivery
WO2025166259A1 (en) Mineral binding mrna lipid nanoparticles
EP4658324A1 (en) Process for producing dna formulations with lipopolymer delivery systems
Vitro Chemical and Molecular Conjugates I

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application